Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing

Peregrine Pharma New (NASDAQ: PPHM)

$0.59 USD $0.01 (1.72%)
Last Price $0.59
Net Change $0.01 (1.72%)
Bid $0.51
Ask Price $0.64
Open Price $0.58
Previous Close Price $0.58
High Price $0.6
Low Price $0.58
Number of Trades 5,947
Volume 1,620,700
Fifty Two Week High $0.77 (2017-03-13)
Fifty Two Week Low $0.28 (2017-01-30)
Average Daily Volume 3,448,365
Share Outstanding 297,710 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $-0.04 (2017-03-13)
2nd Quarter Earnings $-0.02 (2016-12-12)
3nd Quarter Earnings $-0.05 (2016-09-08)
4th Quarter Earnings $-0.05 (2016-07-14)
PE Ratio $0
EPS Growth $60.71
Recent Earnings $-0.04
Annual EPS $-0.16
Last Quarter EPS $
Market Capitalization $0.18B
Insider Shareholders % 0.0485%
Annual Revenue $0B
No. Shares Outstanding 297,710
Inst. Shareholder % 10.37%
Annual Net Income $-0.03B
TTM Net Profit Margin $-59.43
1-Year Return 47.5%
3-Year Return -67.93%
5-Year Return 43.9%
5-Year Revenue Growth 231.28%
5-Year Earnings Growth -50%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD 60.709999%
Dividends per Share $
Stock Split Ratio 1-5
Beta 2.06
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.

PPHM News & Stock Updates